
Matteo Foschi
Articles
-
Nov 29, 2024 |
nature.com | Matteo Foschi |Raffaele Ornello |Federico De Santis |Michele Romoli |Federica De Santis |Francesca Gabriele | +1 more
AbstractThe use of antiplatelet therapy (APT) is prevalent among the general population, sometimes without clear indications. We provided updated figures on the incidence and prognosis of first-ever intracerebral hemorrhage occurring on APT (APT-ICH) over 10 years in a population-based stroke registry and investigated the rates of inappropriate APT prescription.
-
May 14, 2024 |
jnnp.bmj.com | Federico De Santis |Michele Romoli |Matteo Foschi |Francesco Domenico Sciancalepore
Meta-analysis was performed according to random effects modelling15 to take into account unmeasured confounders and differences in setting across studies. Heterogeneity across cohort studies was assessed with Cochrane’s Q statistics and I2 statistics. Random effects models were used to estimate summary risk ratio (95% CIs) using Cochrane’s Review Manager (RevMan V.5.3) software and R studio V.4.2.2 (RStudio PBC) for meta-regression.
-
Jan 18, 2024 |
jnnp.bmj.com | Federico De Santis |Michele Romoli |Matteo Foschi |Francesco Domenico Sciancalepore
AbstractBackground Leisure-time physical activity (LTPA) protects against vascular diseases. Whether and to what extent different levels of LTPA, including lower ones, benefit stroke prevention is still unclear.
-
Nov 10, 2023 |
frontiersin.org | Matteo Foschi |Eleonora De Matteis |Federico De Santis
IntroductionAccording to previous studies, increased systolic blood pressure (SBP) after endovascular treatment (EVT) in patients with acute ischemic stroke (AIS) has been correlated with worse clinical outcomes and an increased risk of intracranial hemorrhage (ICH) (1–7). The most recent guidelines, however, recommended a decent blood pressure target to be <180/105 mmHg in the first 24 h after endovascular treatment (8, 9).
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →